Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection

Journal of Viral Hepatitis

Volumn 20, Issue 12, 2013, Pages 829-837

  Casado, J L ^a   Quereda, C ^a   Moreno, A ^a   Perez Elias M J ^a   Marti Belda P ^a   Moreno, S ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

fibrosis; hepatitis C; histological; interferon therapy; regression; transient elastography

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; THROMBOELASTOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE;

FIBROSIS; HEPATITIS C; HISTOLOGICAL; INTERFERON THERAPY; REGRESSION; TRANSIENT ELASTOGRAPHY;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; COINFECTION; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84887566606     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12108     Document Type: Article

References (38)

1. Graham CS, Baden LR, Yu E, et al,. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569.
2. Soto B, Sanchez-Quijano A, Rodrigo L, et al,. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
3. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al,. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
4. Chung RT, Andersen J, Volberding P, et al,. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
5. Coverdale SA, Khan MH, Byth K, et al,. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004; 99: 636-644.
6. Veldt BJ, Heathcote EJ, Wedemeyer H, et al,. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684.
7. Camma C, Di Bonna D, Schepis F, et al,. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333-342.
8. Poynard T, McHutchison J, Manns M, et al,. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313.
9. Bani-Sadr F, Lapidus N, Bedossa P, et al,. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008; 46: 768-774.
10. Thein HH, Yi Q, Dore GJ, Krahn MD,. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979-1991.
11. Operskalski EA, Kovacs A,. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8: 12-22.
12. Neukam K, Recio E, Camacho A, et al,. Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry. Eur J Gastroenterol Hepatol 2010; 22: 801-807.
13. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J,. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83: 127-134.
14. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.
15. Moreno S, Garcia-Samaniego J, Moreno A, et al,. Non invasive diagnosis of liver fibrosis in patients with HIV infection and HBV/HCV coinfection. J Viral Hepat 2009; 16: 249-258.
16. Castera L, Forns X, Alberti A,. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847.
17. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM,. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-738.
18. Lissen E, Clumeck N, Sola R, et al,. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006; 20: 2175-2181.
19. Di Martino V, Thevenot T, Boyer N, et al,. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. AIDS 2002; 16: 441-445.
20. Sarmiento-Castro R, Horta A, Vasconcelos O, et al,. Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV e HIV co-infection. J Infect 2007; 54: 609-616.
21. Sobesky R, Mathurin P, Charlotte F, et al,. Modelling the impact of interferon treatment on liver fibrosis progression in chronic hepatitis c: a dynamic view. The Multivirc Group. Gastroenterology 1999; 116: 378-386.
22. Marcellin P, Boyer N, Gervais A, et al,. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alfa therapy. Ann Intern Med 1997; 127: 875-881.
23. Andersen ES, Moessner EK, Christensen PB, et al,. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2011; 23: 41-44.
24. Barreiro P, Labarga P, Martin-Carbonero L, et al,. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Antivir Ther 2006; 11: 869-877.
25. Jang JY, Shao RX, Lin W, et al,. HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol 2011; 54: 612-620.
26. Bruno R, Gallastri S, Sacchi P, et al,. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 2010; 59: 513-520.
27. Chakraborty JB, Oakley F, Walsh MJ,. Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int J Hepat 2012; 2012: Article ID 648915. doi: 10.1155/2012/648915.
28. Friedman SL,. Fibrogenic cell reversion underlies fibrosis regression in liver. Proc Natl Acad Sci USA 2012; 109: 9230-9231.
29. Kisseleva T, Brenner DA,. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006; 21 (Suppl 3): S84-S87.
30. Giannelli G, Bergamini C, Marinosci F, et al,. Antifibrogenic effect of IFN-α2b on hepatic stellate cell activation by human hepatocytes. J Interferon Cytokine Res 2006; 26: 301-308.
31. Tsubota A, Kumada H, Chayama K, et al,. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection. J Hepatol 1997; 27: 49-55.
32. Warren A, Cogger VC, Fraser R, DeLeve L, McCuskey RS, Le Couteur DG,. The effects of old age on hepatic stellate cells. Curr Gerontol Geriatr Res 2011; 2011: Article ID 439835. doi: 10.1155/2011/439835.
33. Collazos J, Asensi V, de la Fuente B, Cartõn JA,. The Effect of Unsuccessful Treatment with Peginterferon and Ribavirin on the Liver Fibrosis Course of HIV/HCV-coinfected Patients. Curr HIV Res 2012; 10: 679-687.
34. Shiffman ML, Morishima C, Dienstag JL, et al,. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009; 137: 1986-1994.
35. Berenguer J, Alvarez-Pellicer J, Miralles P, et al,. Sustained virological response to interferon plus ribavirin reduces liver related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-413.
36. Bruno S, Stroffolini T, Colombo M, et al,. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
37. Sanchez-Conde M, Montes-Ramirez ML, Miralles P, et al,. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010; 17: 280-286.
38. Stebbing J, Farouk L, Panos G, et al,. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44: 214-219.